Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Inclusion Criteria: 1. Patients with multiple myeloma eligible for autologous hematopoietic stem cell transplantation; 2. Secretory MM should have measurable markers, including: 1. specific M protein value (≥5g/L)； 2. and/or involved flc ≥100mg/L； 3. and/or measurable extramedullary foci (diameter\>1cm on CT); 3. Age ≥ 18 years and ≤ 70 years, male or female; 4. PR and above are obtained after induction therapy according to the IMWG response criteria; 5. Mononuclear cells ≥2×10\^8/kg body weight, CD34+ cells≥2×10\^6/kg body weight; 6. ECOG 0-2, with life expectance ≥3 months; 7. ALT/AST level ≤2.5 times of the maximum of normal range; total bilirubin≤2 times of normal maximum； 8. Neutrophil count≥ 1.5×10\^9/L, platelet count ≥50×10\^9/L; 9. Normal Left ventricular ejection fraction , NYHA stage 1, lung function GOLD stage 1; 10. Willing to accept the possibility of potential adverse events and efficacy observation by the investigators; 11. Being able to understand and signing the written consent, which should be signed prior to any procedure of the trial. Exclusion Criteria: 1. With ≥2 degree of peripheral neuropath or with pain; 2. Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed; 3. With severe pulmonary/cardiac disfunction (including history of QT interval elongation, ventricular tachycardia, ventricular fibrillation, myocardial infraction) or other severe organ malfunction; 4. Patients in pregnancy or lactation; 5. Allergic constitution or being allergic to any drug within the regimen of the trial; 6. With uncontrolled mental diseases; 7. With active infection; 8. With active hepatitis; 9. HIV positive; 10. History of other malignant tumor within 5 years prior to enrollment; except for the case of in situ cervical cancer and non-malignant melanoma; 11. With other conditions that the investigators think unfit for the trial.